ReviewExperimental & molecular medicine2013
Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine.
Review in Experimental & molecular medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 605 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
605 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Pooled it
- Efficacy and safety of mesenchymal stem cell therapy in liver cirrhosis: a systematic review and meta-analysis.Stem cell research & therapy · 2023Pooled it
- Potential Role for Stem Cell Regenerative Therapy as a Treatment for Degenerative Disc Disease and Low Back Pain: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Pooled it
- Pooled it
- A single step, centrifuge-free method to harvest bone marrow highly concentrated in mesenchymal stem cells: results of a pilot trial.International orthopaedics · 2022Trial
- Bone Marrow Aspirate Concentrate versus Platelet Rich Plasma or Hyaluronic Acid for the Treatment of Knee Osteoarthritis.Medicina (Kaunas, Lithuania) · 2021Trial
- Cryopreservation of adipose tissue for nanofat production: biological principles, workflow standardisation, and regulated biobanking.Cell and tissue banking · 2026Review
- Surviving the Nucleus Pulposus Desert: Next-Generation Strategies for Intervertebral Disc Cell Therapy.JOR spine · 2026Article
- Advancing Type 1 Diabetes Treatment: 3 PM-Oriented Innovations in Islet Transplantation and Biomaterial Engineering.Diabetes/metabolism research and reviews · 2026Review
- Special Issue "Feature Reviews in Mesenchymal Stem Cells".Biomedicines · 2026Article
- Stem Cell Therapy for Stress Urinary Incontinence: Why Has Clinical Success Remained Limited?International urogynecology journal · 2026Article
- Early histological advantage of CD271-positive adipose-derived mesenchymal stromal cells isolated from the infrapatellar fat pad in experimental knee osteoarthritis.BMC musculoskeletal disorders · 2026Article
- A Universal Bio-Hybrid Nanoparticle Backpack Platform Endows Stem Cells with Microenvironmental Resilience and Sustained Paracrine Signaling.Nano-micro letters · 2026Article
- Cryogel-based therapeutic platforms for disease modification in osteoarthritis.npj biomedical innovations · 2026Review
- Restoring neuroplasticity after CNS trauma: cell therapy approaches in spinal cord and traumatic brain injury.Journal of translational medicine · 2026Review
- HA-UCMSCs as an innovative therapy for treating multiple organ dysfunction syndrome.Stem cell research & therapy · 2026Article
- A Brief Overview and Update of Regenerative Medicine for the Treatment of Musculoskeletal Conditions.Current reviews in musculoskeletal medicine · 2026Review
- Recent Advances in Exosome-Based Therapeutic Strategies for Acute Lung Injury: Mechanisms and Translational Advances.Antioxidants (Basel, Switzerland) · 2026Review
- Therapeutic potential of umbilical cord-derived mesenchymal stem/stromal cells versus their conditioned media on treatment of polycystic ovary In-vivo.Molecular and cellular biochemistry · 2026Article
545 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cells (MSCs) are partially defined by their ability to differentiate into tissues including bone, cartilage and adipose in vitro, but it is their trophic, paracrine and immunomodulatory functions that may have the greatest therapeutic impact in vivo. Unlike pharmaceutical treatments that deliver a single agent at a specific dose, MSCs are site regulated and secrete bioactive factors and signals at variable concentrations in response to local microenvironmental cues. Significant progress has been made in understanding the biochemical and metabolic mechanisms and feedback associated with MSC response. The anti-inflammatory and immunomodulatory capacity of MSC may be paramount in the restoration of localized or systemic conditions for normal healing and tissue regeneration. Allogeneic MSC treatments, categorized as a drug by regulatory agencies, have been widely pursued, but new studies demonstrate the efficacy of autologous MSC therapies, even for individuals affected by a disease state. Safety and regulatory concerns surrounding allogeneic cell preparations make autologous and minimally manipulated cell therapies an attractive option for many regenerative, anti-inflammatory and autoimmune applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.